CytoAgents
PrivateLast Round
Grant
Oct 1, 2025
Est. Valuation
$52M
Total Funding Raised
$15.3M
Company Overview
CytoAgents operates in Healthcare & Life Sciences and is based in Pittsburgh, Pennsylvania. Its latest recorded funding round was a Grant round in October 2025.
CytoAgents is a biotechnology company that develops innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CytoAgents Comparables
Compare CytoAgents with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Poolbeg Pharma plc | 88% | |
| Taran Therapeutics, Inc. | 73% | |
| Incyte Corporation | 70% |
For institutional investors. Book with your work email.
CytoAgents Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 1, 2025 | ||||
| Grant | Sep 25, 2024 | ||||
| Series A | May 11, 2023 | ||||
| Grant | Oct 3, 2021 | ||||
| VC Round | Aug 10, 2021 | ||||
Accelerator | Apr 5, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CytoAgents Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AlphaLab Health | Accelerator |
| Pittsburgh Life Sciences Greenhouse | Seed |
| National Cancer Institute | Grant |
| National Institute of Allergy and Infectious Diseases | Grant, Accelerator |
| NIH RADx | Grant, Accelerator |
| AHN | Accelerator |
| Richard King Mellon Foundation | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 77% MoM.
- Apr 18, 2026
Monthly visitors increased 541% MoM, reaching 2.3K.
For institutional investors. Book with your work email.
CytoAgents Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CytoAgents's valuation, stock price, and market status.
Is CytoAgents a public or private company?
CytoAgents is a private company.
What is the current stock price of CytoAgents?
CytoAgents is a private company, so its shares have no public market price. Caplight tracks CytoAgents's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CytoAgents worth (valuation)?
CytoAgents's valuation is estimated at $52.0M based on funding round data.
Can I buy CytoAgents stock?
CytoAgents shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CytoAgents's last funding round?
CytoAgents's most recent funding round was Grant on October 1, 2025.
Who are the main investors in CytoAgents?
Key investors in CytoAgents include Pittsburgh Life Sciences Greenhouse, NIH RADx, Richard King Mellon Foundation, Penn Cove Group.
Will CytoAgents IPO soon?
No public IPO plans have been announced for CytoAgents.
How can I track CytoAgents secondary market activity?
Caplight tracks bids, offers, and trades in CytoAgents's shares on secondary markets.